38.57+0.97 (+2.58%)
At close: 4:02PM EDT
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Performance Outlook
| Previous Close | 37.60 |
| Open | 37.87 |
| Bid | 38.55 x 4000 |
| Ask | 38.57 x 38500 |
| Day's Range | 37.81 - 38.70 |
| 52 Week Range | 29.99 - 43.08 |
| Volume | 52,829,481 |
| Avg. Volume | 31,922,751 |
| Market Cap | 215.15B |
| Beta (5Y Monthly) | 0.65 |
| PE Ratio (TTM) | 22.60 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.56 (4.04%) |
| Ex-Dividend Date | Jan 28, 2021 |
| 1y Target Est | N/A |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-23% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
View moreRelated Research
- Yahoo Finance UK
UK hospitality chiefs warn on COVID passports in economy reopening plans
Britain's biggest hospitality firms also called on prime minister Boris Johnson to stick with the current dates on the roadmap out of lockdown.
- Barrons.com
These 2 Startups Are Searching for Cancer’s Hidden Weaknesses. What to Know.
Biotech startups Repare Therapeutics and Ideaya Biosciences, along with Big Pharma partners, are now leading clinical trials for new drugs.
- Motley Fool
Should You Buy Pfizer in April?
It's been 13 months since Pfizer (NYSE: PFE) announced that it was partnering with BioNTech to develop a COVID-19 vaccine. Since then, Pfizer's shares are up more than 26%. Should you buy Pfizer in April?
© 2021 Verizon Media. All rights reserved.
